GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Bionik Laboratories BNKL · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2023

Revenue

$1.8m

FY2014FY2023

Net income

−$4.9m

FY2014FY2023

Free cash flow

−$3.4m

FY2014FY2023

Shareholders' equity

−$1.6m

FY2014FY2023

Income statement

Fiscal years

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Revenue$1.8m$1.3m$1.2m$2.2m$3.2m$987,431$571,945—$6,000$5,200
Research and development$903,219$998,516$1.5m$3.9m$3.2m$2.8m$2.7m$1.4m$1.3m—
Operating income−$4.8m−$4.8m−$6.2m−$11.2m−$7.3m−$10.0m−$8.0m−$6.6m−$29,528−$13,109
Net income−$4.9m−$10.4m−$13.6m−$24.9m−$10.6m−$14.7m−$3.9m$1.0m−$29,528−$13,109
Diluted earnings per share-0.72-1.51-2.31-4.86-2.06-5.64-5.801.61-0.06-0.04

Balance sheet

At each fiscal year end

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Total assets$3.4m$4.7m$8.8m$18.5m$30.7m$28.6m$29.0m$6.2m$3,242$4,422
Cash and short-term investments$427,383$2.0m$608,348$2.3m$446,779$507,311$543,650$5.4m$3,242$4,422
Total liabilities$5.0m$1.7m$5.5m$5.2m$3.3m$8.1m$5.8m$6.0m$42,580$14,232
Debt$2.4m—$3.7m$2.1m—$51,479$2.6m$5.1m$1.0m—
Shareholders' equity−$1.6m$2.9m$3.3m$13.3m$27.4m$20.5m$23.2m$263,906−$39,338−$9,810
Shares outstanding7m7m6m5m5m3m1m1m0m0m

Cash flow

Fiscal years

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Cash from operations−$3.4m−$4.1m−$4.6m−$9.1m−$9.2m−$7.7m−$7.0m−$4.7m−$13,204−$14,609
Capital spending−$8,694−$12,500−$4−$159,645−$101,779−$21,567−$170,790−$42,863−$109—
Free cash flow−$3.4m−$4.2m−$4.6m−$9.2m−$9.3m−$7.7m−$7.2m−$4.8m−$13,313−$14,609

Latest quarters

By quarter end

Mar 2023Dec 2022Sept 2022Jun 2022Mar 2022Dec 2021Sept 2021Jun 2021
Revenue$501,114$575,054$486,205$242,829$191,262$183,262$227,905$671,283
Operating income−$1.3m−$1.0m−$1.1m−$1.4m−$1.4m−$1.5m−$1.0m−$801,885
Net income−$1.4m−$1.1m−$1.1m−$1.4m−$2.0m−$12.2m−$1.3m−$450,912
Diluted earnings per share-0.21-0.16-0.17-0.20-0.29-2.06-0.21-0.08
Cash from operations———−$1.0m−$1.0m−$1.0m——
Total assets$3.4m$3.7m$3.8m$4.0m$4.7m$6.0m$12.5m$8.7m
Cash and short-term investments$427,383$685,202$397,746$1.3m$2.0m$3.4m$4.8m$541,587
Debt$2.2m$1.6m$790,752$503,467—$8.7m$8.5m$3.9m
Shareholders' equity−$1.6m−$521,906$523,018$1.6m$2.9m−$4.4m$2.3m$2.9m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-5.7%12.8%73.0%
Operating income-24.6%-13.6%87.5%
Net income-41.7%-19.6%87.1%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-311.7%-420.2%-415.9%—
Net margin-498.7%-839.0%-743.0%—

Valuation history

At each fiscal year end

FY2023FY2022FY2021FY2015
Price to earnings-0.1-0.0—-0.0
Price to sales0.40.20.00.1

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return900%-100%142%2758%235%383%45%-62%-74%-42%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 150-to-1 reverse split · 30 Oct 2018
  • 1.2032-to-1 reverse split · 13 Feb 2015
  • 22.75-for-1 split · 16 Jul 2013

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.